Competition to get fiercer for Olmetec generic market

Published: 2011-01-24 06:59:00

Updated: 2011-01-24 06:59:00

Korean companies are poised to step up their marketing in domestic Olmetec generics market, which is forecast to become more competitive than even early this year, according to industry source.

The Korea Food and Drug Administration will reportedly approve about 130 Olmetec generics next month...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK